Medific Inc. has described substituted thiazolidinedione derivatives acting as sterol regulatory element binding protein (SREBP; SREBF1) inhibitors reported to be useful for the treatment of cancer, particularly brain cancer.
Hangzhou Polymed Biopharmaceuticals Inc. has synthesized IL-1 receptor-associated kinase 4 (IRAK-4) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Annova Biotechnology Co. Ltd. has disclosed substituted fused heterocyclic compounds acting as ATR kinase inhibitors reported to be useful for the treatment of cancer.
Research at Insilico Medicine Inc. has led to the development of CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, infections, autoimmune disorders and inflammation.
Galectin-3 (LGALS3) and/or galectin-9 (LGALS9) inhibitors are reported in a Galecto Biotech AB patent as potentially useful for the treatment of cancer, autoimmune disease, fibrosis, cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among others.
A Chiesi Farmaceutici SpA patent details cyclohexane acid derivatives acting as lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists and thus reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Jeil Pharmaceutical Co. Ltd. has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, ulcerative colitis, rheumatoid arthritis, autoimmune disease, cardiovascular disorders and dermatological and inflammatory disorders and neurological disorders, among others.
RSS